Ultragenyx Pharmaceutical | RARE - Pre Tax Profit


Ultragenyx Pharmaceutical reported $-184M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Esperion Therapeutics USD 63.67M 95M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Insmed USD -162.1M 164.84M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Kyowa Hakko Kirin JPY 13.92B 25.37B Mar/2026
MacroGenics USD -14.93M 31.75M Dec/2025
Moderna USD -799M 612M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026
Xoma USD 15.98M 24.58M Jun/2024